← Back to Search

Deep Brain Stimulation

Deep Brain Stimulation for Tourette Syndrome

N/A
Recruiting
Led By Christopher Butson, PhD
Research Sponsored by University of Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial involves using a small implantable device to help control severe tics in patients with Tourette syndrome. The device works by monitoring brain activity and sending electrical signals to specific brain areas to stop the tics. This method has been increasingly used for symptom management in severe cases of Tourette syndrome.

Who is the study for?
This trial is for adults with severe Tourette Syndrome (TS) that's not improved with medication. They must have a confirmed diagnosis by specialists, stable mental health if they have depression, and a significant impact on their life due to TS. Pregnant women or those planning pregnancy during the study are excluded, as well as individuals with drug-induced tics, recent suicide attempts or substance abuse, metal in the head, previous brain surgery, or other serious health issues.
What is being tested?
The trial tests an FDA-approved device called 'Medtronic Percept PC', which is implanted into the brain to detect and suppress tic symptoms in TS patients. It targets specific areas of the brain and records neural signals to understand how tics occur and can be controlled.
What are the potential side effects?
Potential side effects may include discomfort at implantation sites, risk of infection from surgery, possible changes in mood or behavior due to stimulation of brain areas involved in emotion regulation. There might also be risks associated with any surgical procedure such as bleeding or adverse reactions to anesthesia.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Yale Global Tic Severity Scale_(YGTSS) - Total Tic Score

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Medtronic Percept NeurostimulatorExperimental Treatment1 Intervention
This is a deep brain stimulator that can also record brain signals and deliver stimulation through a control algorithm based on brain activity.

Find a Location

Who is running the clinical trial?

University of FloridaLead Sponsor
1,401 Previous Clinical Trials
767,001 Total Patients Enrolled
7 Trials studying Tourette Syndrome
134 Patients Enrolled for Tourette Syndrome
National Institute of Neurological Disorders and Stroke (NINDS)NIH
1,378 Previous Clinical Trials
652,184 Total Patients Enrolled
12 Trials studying Tourette Syndrome
1,770 Patients Enrolled for Tourette Syndrome
Christopher Butson, PhDPrincipal InvestigatorUniversity of Florida
2 Previous Clinical Trials
123 Total Patients Enrolled

Media Library

Medtronic Percept Neurostimulator (Deep Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT05371041 — N/A
Tourette Syndrome Research Study Groups: Medtronic Percept Neurostimulator
Tourette Syndrome Clinical Trial 2023: Medtronic Percept Neurostimulator Highlights & Side Effects. Trial Name: NCT05371041 — N/A
Medtronic Percept Neurostimulator (Deep Brain Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05371041 — N/A
~3 spots leftby Aug 2026